The 20 references in paper A. Mudunov M., M. Narimanov N., D. Safarov A., А. Мудунов М., М. Нариманов Н., Д. Сафаров А. (2017) “НОВЫЕ ВОЗМОЖНОСТИ ИММУНОТЕРАПИИ В ЛЕЧЕНИИ РАСПРОСТРАНЕННОГО РЕЦИДИВНОГО ПЛОСКОКЛЕТОЧНОГО РАКА ОРГАНОВ ГОЛОВЫ И ШЕИ // NEW OPPORTUNITIES FOR IMMUNE THERAPY IN PATIENTS WITH DISSEMINATED RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK” / spz:neicon:ogsh:y:2017:i:2:p:99-105

1
International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr (accessed Jan 13, 2016).
(check this in PDF content)
2
Seiwert T. Y., Salama J. K., Vokes E. E. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007;4(3):156–71. DOI: 10.1038/ncponc0750. PMID: 17327856.
(check this in PDF content)
3
Vermorken J. B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359(11):1116–27. DOI: 10.1056/NEJMoa0802656. PMID: 18784101. Таблица 4. Частота объективного ответа на лечение пембролизумабом в исследовании KEYNOTE-055 (адаптировано из [17]), N = 171 Table 4. Objective response rate in patients receiving pembrolizumab in the KEYNOTE-055 study (adapted from [17]), N = 171 Показатель Parameter Число пациентов, n (%) Number of patients, n (%) Общая частота ответов Overall response rate Полный ответ Complete response Частичная регрессия опухоли Partial tumor regression Стабилизация процесса Stabilization of the process Прогрессирование Progression 28 (16) 1 (1) 27 (16) 33 (19) 87 (51) Статус по ВПЧ: HPV status:
(check this in PDF content)
4
Seiwert T. Y., Zuo Z., Keck M. K. et al. Integrative and comparative genomic analysis of HPV-positive and HPVnegative head and neck squamous cell carcinomas. Clin Cancer Res 2015;21(3):632–41. DOI: 10.1158/1078–0432.CCR-13–3310. PMID: 25056374.
(check this in PDF content)
5
Keck M. K., Zuo Z., Khattri A. et al. Integrative analysis of head and neck cancer identifi es two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res 2015;21(4):870–81. DOI: 10.1158/1078–0432.CCR-14–2481. PMID: 25492084.
(check this in PDF content)
6
The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576–82. DOI: 10.1038/nature14129. PMID: 25631445.
(check this in PDF content)
7
Keir M. E., Butte M. J., Freeman G. J., Sharpe A. H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677–704. DOI: 10.1146/annurev. immunol. 26.021607.090331. PMID: 18173375.
(check this in PDF content)
8
Latchman Y., Wood C. R., Chernova T. et al. PD–L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Rev Immunol 2001;2 (3):261–68. DOI: 10.1038/85330. PMID: 11224527.
(check this in PDF content)
9
Pardoll D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252–64. DOI: 10.1038/nrc3239. PMID: 22437870.
(check this in PDF content)
10
McDermott D. F., Atkins M. B. PD-1 as a potential target in cancer therapy. Cancer Med 2013;2(5):662–73. DOI: 10.1002/cam4.106. PMID: 24403232.
(check this in PDF content)
11
Lyford-Pike S., Peng S., Young G. D. et al. Evidence for a role of the PD-1: PD–L1 pathway in immune resistance of HPVassociated head and neck squamous cell carcinoma. Cancer Res 2013;73(6):1733–41. DOI: 10.1158/0008–5472.CAN-12–2384. PMID: 23288508.
(check this in PDF content)
12
Saloura V., Zou Z., Koeppen H. Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD–L1, and other immune checkpoints in head and neck cancer. Proc Soc Am Clin Oncol 2014;32(5s): 6009 (abstr).
(check this in PDF content)
13
Ferris R., Blumenschein G., Fayette J. et al. Nivolumab for recurrent squamouscell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856–67. DOI: 10.1056/NEJMoa1602252. PMID: 27718784.
(check this in PDF content)
14
Hamid O., Robert C., Daud A. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369 (2):134–44. DOI: 10.1056/NEJMoa1305133. PMID: 23724846..
(check this in PDF content)
15
Garon E. B., Rizvi N. A., Hui R. et al. Pembrolizumab for the treatment of nonsmall-cell lung cancer. N Engl J Med 2015;372(21):2018–28. DOI: 10.1056/NEJMoa1501824. PMID: 25891174.
(check this in PDF content)
16
Topalian S. L., Hodi F. S., Brahmer J. R. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443–54. DOI: 10.1056/NEJMoa1200690. PMID: 22658127.
(check this in PDF content)
17
Bauml J., Siewert T., Pfister D. G. et al. Preliminary results from KEYNOTE-055: Pembrolizumab after Cisplatin and Cetuximab failure in Head and Neck squamous cell carcinoma. ASCO Annual Meeting, Best of ASCO designation: 2016. J Clin Oncol. 2016;34 (suppl): abstr 6011.
(check this in PDF content)
18
Machiels J. P., Haddad R. I., Fayette J. et al: Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an openlabel, randomised phase 3 trial. Lancet Oncol 2015;16(5):583–94. DOI: 10.1016/S1470–2045(15) 70124–5. PMID: 25892145
(check this in PDF content)
19
Seiwert T. Y., Fayette J., Cupissol D. et al. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 2014;25(9):1813–20. DOI: 10.1093/annonc/mdu216. PMID: 24928832.
(check this in PDF content)
20
Chow L. Q. M., Haddad R., Gupta S. et al: Antitumor activity of pembrolizuamb in biomarker-unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: Results from
(check this in PDF content)